Navigation Links
Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health

SAN FRANCISCO, Oct. 30 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) is pleased to announce the formal establishment of a not-for-profit affiliate, the Canadian Foundation for Global Health (CFGH). CFGH was founded under Canadian Federal Law as a not-for-profit Canadian Corporation headquartered in Ottawa, Ontario, Canada. Under the leadership of Dr. Michael E. Shannon, a founding Director and the foundations' newly appointed President, it is anticipated that the foundation will attract a broad spectrum of the most highly qualified scientists, infectious disease specialists and other medical health professionals from diverse fields of interest to serve on its Board of Directors, Science Advisory Board or as Principal Investigators.

Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation's profit follows its' social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to our research projects, but it is envisioned that as Medizone's products and treatments become ready for market, the foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the county's needs and the availability of international assistance; we intend to make effort through both the for-profit and the non-profit to make affordable medical solutions as widely available as possible for the people of the planet.

Medizone International, Inc., is a research and development stage company engaged in the development of novel technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Web site:

Investor Relations: 800-953-3350

SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
2. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
5. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
6. China Yingxia International, Inc. Appoints New Vice President of Finance
7. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
8. Sangui BioTech International, Inc. Files Remaining Reports
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
11. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
Breaking Biology News(10 mins):